These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8866502)

  • 21. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease dyskinesias.
    Nutt JG; Gancher ST
    Neurology; 1994 Jun; 44(6):1187; author reply 1187-8. PubMed ID: 8208427
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease.
    Gomez Arevalo G; Jorge R; Garcia S; Scipioni O; Gershanik O
    Mov Disord; 1997 May; 12(3):277-84. PubMed ID: 9159719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleus.
    Wenzelburger R; Zhang BR; Poepping M; Schrader B; Müller D; Kopper F; Fietzek U; Mehdorn HM; Deuschl G; Krack P
    Ann Neurol; 2002 Aug; 52(2):240-3. PubMed ID: 12210799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs in the future treatment of Parkinson's disease.
    Djaldetti R; Melamed E
    J Neurol; 2002 Sep; 249 Suppl 2():II30-5. PubMed ID: 12375061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
    Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
    Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.
    Pal PK; Sathyaprabha TN; Tuhina P; Thennarasu K
    Mov Disord; 2007 Feb; 22(3):420-4. PubMed ID: 17230476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome.
    Bédard MA; Pillon B; Dubois B; Duchesne N; Masson H; Agid Y
    Brain Cogn; 1999 Jul; 40(2):289-313. PubMed ID: 10413563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
    Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
    Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological pallidotomy with glutamate antagonists.
    Greenamyre JT
    Ann Neurol; 1996 May; 39(5):557-8. PubMed ID: 8619538
    [No Abstract]   [Full Text] [Related]  

  • 39. Parkinson's disease dyskinesias.
    Quinn NP
    Neurology; 1994 Jun; 44(6):1187; author reply 1187-8. PubMed ID: 8208428
    [No Abstract]   [Full Text] [Related]  

  • 40. [Unpleasant or painful reactions of Parkinson's disease and of the neuroleptic therapy (paresthesia, impatience, cramps, akathisia). Their improvement by alimemazine].
    Sigwald J; Raymondeaud C
    Sem Hop; 1968 Nov; 44(47):2897-9. PubMed ID: 4307328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.